PharmacyCodes



Bentiromido [INN-Spanish] en es it fr

Bentiromido [INN-Spanish] Brand names, Bentiromido [INN-Spanish] Analogs

Bentiromido [INN-Spanish] Brand Names Mixture

  • No information avaliable

Bentiromido [INN-Spanish] Chemical_Formula

C23H20N2O5

Bentiromido [INN-Spanish] RX_link

No information avaliable

Bentiromido [INN-Spanish] fda sheet

Bentiromido [INN-Spanish] msds (material safety sheet)

Bentiromido [INN-Spanish] Synthesis Reference

No information avaliable

Bentiromido [INN-Spanish] Molecular Weight

404.415 g/mol

Bentiromido [INN-Spanish] Melting Point

241 oC

Bentiromido [INN-Spanish] H2O Solubility

No information avaliable

Bentiromido [INN-Spanish] State

Solid

Bentiromido [INN-Spanish] LogP

3.201

Bentiromido [INN-Spanish] Dosage Forms

No information avaliable

Bentiromido [INN-Spanish] Indication

Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.

Bentiromido [INN-Spanish] Pharmacology

Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada.

Bentiromido [INN-Spanish] Absorption

No information avaliable

Bentiromido [INN-Spanish] side effects and Toxicity

Symptoms of overdose include shortness of breath and troubled breathing.

Bentiromido [INN-Spanish] Patient Information

Bentiromido [INN-Spanish] Organisms Affected

Humans and other mammals